Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixabepilone in Advanced Urothelial Carcinoma
NCT00021099Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2001
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixabepilone in urothelial carcinoma (UC), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 3 years. Started Jun 2001; status: completed.
02
Drugs
ixabepilone
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT00021099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00021099.